Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that investors with losses in Unicycive Therapeutics (UNCY) can seek lead plaintiff status in an ongoing securities fraud class action, with a deadline of November 2, 2026. The complaint alleges the company failed to disclose that its third-party manufacturing vendor had not been audited for cGMP compliance, creating undisclosed risk that FDA approval of OLC could be delayed.
Key figures
- Lead plaintiff deadline
- November 2, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.